LGND 8-K: Q3 and nine‑month 2025 results furnished as Exhibit 99.1

Q: Which periods are covered by the LGND results?

The release covers the three and nine months ended September 30, 2025 .

Q: How is the information treated under SEC rules?

Under General Instruction B.2. , the information is furnished , not filed, under the Exchange Act.

Q: Where can I find the detailed numbers for LGND’s results?

The detailed figures are in the press release attached as Exhibit 99.1 .

Q: What is the exhibit included with the 8-K?

The filing includes Exhibit 99.1 , the press release dated November 6, 2025.

Q: What exchange and symbol does Ligand trade under?

Ligand’s common stock trades on The Nasdaq Global Market under the symbol LGND .

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Ligand Pharmaceuticals (LGND) announced quarterly results by issuing a press release covering its financial performance for the three and nine months ended September 30, 2025.

The press release is furnished as Exhibit 99.1 and, in line with General Instruction B.2., the information is furnished rather than filed, which limits its treatment under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/06/2025 - 07:08 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

LIGAND PHARMACEUTICALS INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-33093	77-0160744
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
incorporation or organization)		Identification No.)


555 Heritage Drive, Suite 200
Jupiter
Florida						33458
(Address of principal executive offices)						(Zip Code)

(858) 550-7500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	LGND	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.			Description
99.1			Press release dated November 6, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			LIGAND PHARMACEUTICALS INCORPORATED

Date: November 6, 2025			By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What did Ligand (LGND) disclose in this 8-K?

It issued a press release announcing financial results for the three and nine months ended September 30, 2025, furnished as Exhibit 99.1.

Which periods are covered by the LGND results?

The release covers the three and nine months ended September 30, 2025.

How is the information treated under SEC rules?

Under General Instruction B.2., the information is furnished, not filed, under the Exchange Act.

Where can I find the detailed numbers for LGND’s results?

The detailed figures are in the press release attached as Exhibit 99.1.

What is the exhibit included with the 8-K?

The filing includes Exhibit 99.1, the press release dated November 6, 2025.

What exchange and symbol does Ligand trade under?

Ligand’s common stock trades on The Nasdaq Global Market under the symbol LGND.